Cargando…

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant

Detalles Bibliográficos
Autores principales:	Takashita, Emi, Kinoshita, Noriko, Yamayoshi, Seiya, Sakai-Tagawa, Yuko, Fujisaki, Seiichiro, Ito, Mutsumi, Iwatsuki-Horimoto, Kiyoko, Chiba, Shiho, Halfmann, Peter, Nagai, Hiroyuki, Saito, Makoto, Adachi, Eisuke, Sullivan, David, Pekosz, Andrew, Watanabe, Shinji, Maeda, Kenji, Imai, Masaki, Yotsuyanagi, Hiroshi, Mitsuya, Hiroaki, Ohmagari, Norio, Takeda, Makoto, Hasegawa, Hideki, Kawaoka, Yoshihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809508/ https://www.ncbi.nlm.nih.gov/pubmed/35081300 http://dx.doi.org/10.1056/NEJMc2119407

Ejemplares similares

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
por: Takashita, Emi, et al.
Publicado: (2022)

Gargle Lavage as a Safe and Sensitive Alternative to Swab Samples to Diagnose COVID-19: A Case Report in Japan
por: Saito, Makoto, et al.
Publicado: (2020)

Transmission and re-infection of Omicron variant XBB.1.5 in hamsters
por: Halfmann, Peter J., et al.
Publicado: (2023)

Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Previous omicron infection may be protective against reinfection with omicron variant BA.5 for at least 5 months
por: Koga, Michiko, et al.
Publicado: (2023)

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
por: Uraki, Ryuta, et al.
Publicado: (2023)

In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6
por: Takashita, Emi, et al.
Publicado: (2022)

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75
por: Takashita, Emi, et al.
Publicado: (2022)

Diversity of antigenic mutants of influenza A(H1N1)pdm09 virus escaped from human monoclonal antibodies
por: Yasuhara, Atsuhiro, et al.
Publicado: (2017)

Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2
por: Kawaoka, Yoshihiro, et al.
Publicado: (2022)

Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1
por: Uraki, Ryuta, et al.
Publicado: (2023)

Correlation Analysis between Gut Microbiota Alterations and the Cytokine Response in Patients with Coronavirus Disease during Hospitalization
por: Mizutani, Taketoshi, et al.
Publicado: (2022)

Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
por: Takashita, Emi, et al.
Publicado: (2022)

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development
por: Imai, Masaki, et al.
Publicado: (2020)

Longitudinal antibody repertoire in “mild” versus “severe” COVID-19 patients reveals immune markers associated with disease severity and resolution
por: Ravichandran, Supriya, et al.
Publicado: (2021)

A Novel Method to Reduce ELISA Serial Dilution Assay Workload Applied to SARS-CoV-2 and Seasonal HCoVs
por: Pattinson, David, et al.
Publicado: (2022)

Antigenic variants of influenza B viruses isolated in Japan during the 2017‐2018 and 2018‐2019 influenza seasons
por: Kato‐Miyashita, Sari, et al.
Publicado: (2020)

Comparison of Rapid Antigen Tests for COVID-19
por: Yamayoshi, Seiya, et al.
Publicado: (2020)

Evaluation of the fusion partner cell line SPYMEG for obtaining human monoclonal antibodies against influenza B virus
por: SONI, Priyanka, et al.
Publicado: (2018)

Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates
por: Uraki, Ryuta, et al.
Publicado: (2023)

Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccination
por: Yamamoto, Shinya, et al.
Publicado: (2023)

Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination
por: Ishizaka, Aya, et al.
Publicado: (2023)

Comparative Sensitivity of Rapid Antigen Tests for the Delta Variant (B.1.617.2) of SARS-CoV-2
por: Sakai-Tagawa, Yuko, et al.
Publicado: (2021)

Development of an Influenza Rapid Diagnostic Kit Specific for the H7 Subtype
por: Iwatsuki-Horimoto, Kiyoko, et al.
Publicado: (2018)

Characterization of Influenza A(H1N1)pdm09 Viruses Isolated in the 2018–2019 and 2019–2020 Influenza Seasons in Japan
por: Soga, Takuma, et al.
Publicado: (2023)

Antibody titers against SARS-CoV-2 decline, but do not disappear for several months
por: Yamayoshi, Seiya, et al.
Publicado: (2021)

The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner
por: Yamamoto, Mizuki, et al.
Publicado: (2020)

Seroprevalence of SARS-CoV-2 antibodies in dogs and cats during the early and mid-pandemic periods in Japan
por: Yamayoshi, Seiya, et al.
Publicado: (2023)

Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model
por: Chiba, Shiho, et al.
Publicado: (2022)

Antibody-Dependent Enhancement of SARS-CoV-2 Infection Is Mediated by the IgG Receptors FcγRIIA and FcγRIIIA but Does Not Contribute to Aberrant Cytokine Production by Macrophages
por: Maemura, Tadashi, et al.
Publicado: (2021)

Sensitivity of Commercially Available Influenza Rapid Diagnostic Tests in the 2018–2019 Influenza Season
por: Sakai-Tagawa, Yuko, et al.
Publicado: (2019)

Antiviral Susceptibilities of Distinct Lineages of Influenza C and D Viruses
por: Takashita, Emi, et al.
Publicado: (2023)

Characterization of a new SARS-CoV-2 variant that emerged in Brazil
por: Imai, Masaki, et al.
Publicado: (2021)

The Marmoset as an Animal Model of Influenza: Infection With A(H1N1)pdm09 and Highly Pathogenic A(H5N1) Viruses via the Conventional or Tracheal Spray Route
por: Iwatsuki-Horimoto, Kiyoko, et al.
Publicado: (2018)

Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan
por: Fujii, Takayuki, et al.
Publicado: (2022)

Favorable Outcome Following Sotrovimab Monoclonal Antibody in a Patient with Prolonged SARS-CoV-2 Omicron Infection with HIV/AIDS
por: Adachi, Eisuke, et al.
Publicado: (2022)

Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020–March 2022
por: Yamayoshi, Seiya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f72allms41ckgm26jnt3p3e4fh